Phenomics of Vascular Disease: The Systematic Approach to the Combination Therapy

Vascular diseases are usually caused by multifactorial pathogeneses involving genetic and environmental factors. Our current understanding of vascular disease is, however, based on the focused genotype/phenotype studies driven by the “one-gene/one-phenotype” hypothesis. Drugs with “pure target” at individual molecules involved in the pathophysiological pathways are the mainstream of current clinical treatments and the basis of combination therapy of vascular diseases. Recently, the combination of genomics, proteomics, and metabolomics has unraveled the etiology and pathophysiology of vascular disease in a big-data fashion and also revealed unmatched relationships between the omic variability and the much narrower definition of various clinical phenotypes of vascular disease in individual patients. Here, we introduce the phenomics strategy that will change the conventional focused phenotype/genotype/genome study to a new systematic phenome/genome/proteome approach to the understanding of pathophysiology and combination therapy of vascular disease. A phenome is the sum total of an organism’s phenotypic traits that signify the expression of genome and specific environmental influence. Phenomics is the study of phenome to quantitatively correlate complex traits to variability not only in genome, but also in transcriptome, proteome, metabolome, interactome, and environmental factors by exploring the systems biology that links the genomic and phenomic spaces. The application of phenomics and the phenome-wide associated study (PheWAS) will not only identify a systemically-integrated set of biomarkers for diagnosis and prognosis of vascular disease but also provide novel treatment targets for combination therapy and thus make a revolutionary paradigm shift in the clinical treatment of these devastating diseases.

[1]  G. Ehret Genome-Wide Association Studies: Contribution of Genomics to Understanding Blood Pressure and Essential Hypertension , 2010, Current hypertension reports.

[2]  R. Hegele Phenomics, lipodystrophy, and the metabolic syndrome. , 2004, Trends in cardiovascular medicine.

[3]  Zhong Wang,et al.  Clinical Zheng-hou Pharmacology: the Missing Link between Pharmacogenomics and Personalized Medicine? , 2015, Current vascular pharmacology.

[4]  M. Weir Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin–angiotensin system blockade , 2007, Journal of Human Hypertension.

[5]  P. de Knijff,et al.  Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. , 1998, The New England journal of medicine.

[6]  R. Gerlai Phenomics: fiction or the future? , 2002, Trends in Neurosciences.

[7]  Patrice Degoulet,et al.  Phenome-Wide Association Studies on a Quantitative Trait: Application to TPMT Enzyme Activity and Thiopurine Therapy in Pharmacogenomics , 2013, PLoS Comput. Biol..

[8]  Philippe Amouyel,et al.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.

[9]  A. Dominiczak,et al.  Genetic basis of blood pressure and hypertension. , 2012, Trends in genetics : TIG.

[10]  Marylyn D. Ritchie,et al.  Phenome-Wide Association Study (PheWAS) for Detection of Pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network , 2013, PLoS genetics.

[11]  Cai,et al.  GENOME-WIDE ASSOCIATION STUDY META-ANALYSIS REVEALS TRANS-ETHNIC REPLICATION OF MEAN ARTERIAL AND PULSE PRESSURE LOCI , 2022 .

[12]  C. Rotimi,et al.  Genome-wide association study identifies novel loci association with fasting insulin and insulin resistance in African Americans. , 2012, Human molecular genetics.

[13]  D. Duan,et al.  Phenomics of cardiac chloride channels: the systematic study of chloride channel function in the heart , 2009, The Journal of physiology.

[14]  Robert A Hegele,et al.  Phenomics: Expanding the Role of Clinical Evaluation in Genomic Studies , 2010, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[15]  Tom R. Gaunt,et al.  Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk , 2011, Nature.

[16]  B. Meyrick,et al.  Genomics and proteomics of pulmonary vascular disease. , 2011, Comprehensive Physiology.

[17]  M. Tester,et al.  Phenomics--technologies to relieve the phenotyping bottleneck. , 2011, Trends in plant science.

[18]  D. Prabhakaran,et al.  Genomic approaches to coronary artery disease , 2010, The Indian journal of medical research.

[19]  I. Nordon,et al.  The role of proteomic research in vascular disease. , 2009, Journal of vascular surgery.

[20]  S. Omholt,et al.  Phenomics: the next challenge , 2010, Nature Reviews Genetics.

[21]  M. Raizada,et al.  Genomic and proteomic approaches for targeting of angiotensin-converting enzyme2 for cardiovascular diseases , 2008, Current opinion in cardiology.

[22]  M. Caulfield,et al.  Genes for blood pressure: an opportunity to understand hypertension. , 2013, European heart journal.

[23]  M. Gomberg-Maitland,et al.  Current therapeutics and practical management strategies for pulmonary arterial hypertension. , 2011, American heart journal.

[24]  R. Bilder Phenomics: Building Scaffolds for Biological Hypotheses in the Post-Genomic Era , 2008, Biological Psychiatry.

[25]  M. Huynen,et al.  Phenome connections. , 2008, Trends in genetics : TIG.

[26]  D. Duan Phenomics of cardiac chloride channels. , 2013, Comprehensive Physiology.

[27]  Andrew D. Johnson,et al.  Genome-wide association study of blood pressure and hypertension , 2009, Nature Genetics.

[28]  Melissa A. Basford,et al.  Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data , 2013, Nature Biotechnology.

[29]  Marylyn D. Ritchie,et al.  PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease associations , 2010, Bioinform..

[30]  Eric K. Neumann,et al.  Identifying disease-causal genes using Semantic Web-based representation of integrated genomic and phenomic knowledge , 2008, J. Biomed. Informatics.

[31]  A. Rodgers,et al.  Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk. , 2005, The New Zealand medical journal.

[32]  L. Iacoviello,et al.  Gene-environment interactions: implications for cardiovascular disease. , 1999, Cardiologia.

[33]  M. Krawczak,et al.  Genetic studies of common types of obesity: a critique of the current use of phenotypes , 2010, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[34]  C. Ting,et al.  Genome-Wide Association Study of Young-Onset Hypertension in the Han Chinese Population of Taiwan , 2009, PloS one.

[35]  V. Thongboonkerd Genomics, proteomics and integrative ‘omics’ in hypertension research , 2005, Current opinion in nephrology and hypertension.

[36]  Tyrone D. Cannon,et al.  Phenomics: the systematic study of phenotypes on a genome-wide scale , 2009, Neuroscience.

[37]  J. Golledge,et al.  Challenges, current status and future perspectives of proteomics in improving understanding, diagnosis and treatment of vascular disease. , 2009, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[38]  G. Gaetano,et al.  Polymorphisms of the Interleukin-1&bgr; Gene Affect the Risk of Myocardial Infarction and Ischemic Stroke at Young Age and the Response of Mononuclear Cells to Stimulation In Vitro , 2004, Arteriosclerosis, thrombosis, and vascular biology.